Table 4.
Adverse events (AEs)
| AE | Study group (n=43) |
Days until AE (mean±SD) |
Control group (n=43) | Days until AE (mean±SD) |
Management |
| Hepatic encephalopathy | 3 | 0.3±0.6 | 10 | 6.9±9.7 | Anticoma measures |
| Hepatorenal syndrome | 4 | 5.5±5.3 | Terlipressin and albumin | ||
| Leukocytosis | 1 | 2 | Antibiotics shift | ||
| Spontaneous bacterial peritonitis | 4 | 4.8±1.7 | 2 | 1.5±0.7 | Antibiotics adjustments |
| Leukocytosis | 1 | 1 | Antibiotics shift | ||
| Tense ascites causing abdominal pain | 1 | 1 | Tapping of ascites | ||
| Rebleeding after elective endoscopy | |||||
| Bleeding during follow-up upper endoscopy on day 15 | 1 | 15 | 1 | 15 | Injection sclerotherapy and band ligation |
| Rectal bleeding | 1 | 2 | Medical treatment (octreotide/PPI/blood transfusion) | ||
| Rebleeding (haematemesis±melena) | 1 | 5 | Actively bleeding PHG → Medical management | ||
| Rebleeding (haematemesis±melena) | 1 | 7 | Postband ligation ulcer → Hemospray and PPIs | ||
| Rebleeding (haematemesis±melena) | 2 | 3±2.8 | Medical treatment (octreotide/PPI/blood transfusion) | ||
| Rebleeding (haematemesis±melena) | 1 | 15±4.2 | Injection sclerotherapy and band ligation | ||
PHG, portal hypertensive gastropathy; PPI, proton-pump inhibitors.